A detailed history of Blair William & CO transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Blair William & CO holds 536,724 shares of BMY stock, worth $31.6 Million. This represents 0.08% of its overall portfolio holdings.

Number of Shares
536,724
Previous 582,159 7.8%
Holding current value
$31.6 Million
Previous $24.2 Million 14.88%
% of portfolio
0.08%
Previous 0.08%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$39.66 - $51.75 $1.8 Million - $2.35 Million
-45,435 Reduced 7.8%
536,724 $27.8 Million
Q2 2024

Aug 12, 2024

SELL
$40.25 - $52.99 $3.76 Million - $4.95 Million
-93,451 Reduced 13.83%
582,159 $24.2 Million
Q1 2024

May 09, 2024

SELL
$47.98 - $54.4 $9.06 Million - $10.3 Million
-188,760 Reduced 21.84%
675,610 $36.6 Million
Q4 2023

Feb 12, 2024

SELL
$48.48 - $57.85 $12.8 Million - $15.3 Million
-264,198 Reduced 23.41%
864,370 $44.4 Million
Q3 2023

Nov 09, 2023

SELL
$57.89 - $64.73 $3.39 Million - $3.79 Million
-58,545 Reduced 4.93%
1,128,568 $65.5 Million
Q2 2023

Aug 11, 2023

SELL
$63.71 - $70.74 $2.03 Million - $2.26 Million
-31,934 Reduced 2.62%
1,187,113 $75.9 Million
Q1 2023

May 12, 2023

BUY
$65.71 - $74.53 $529,162 - $600,190
8,053 Added 0.66%
1,219,047 $84.5 Million
Q4 2022

Feb 10, 2023

SELL
$68.48 - $81.09 $4.4 Million - $5.21 Million
-64,269 Reduced 5.04%
1,210,994 $87.1 Million
Q3 2022

Nov 09, 2022

BUY
$0.13 - $76.84 $2,074 - $1.23 Million
15,960 Added 1.27%
1,275,263 $90.7 Million
Q2 2022

Aug 10, 2022

BUY
$72.62 - $79.98 $12.8 Million - $14.1 Million
176,326 Added 16.28%
1,259,303 $97 Million
Q1 2022

May 13, 2022

BUY
$61.48 - $73.72 $143,863 - $172,504
2,340 Added 0.22%
1,082,977 $79.1 Million
Q4 2021

Feb 14, 2022

SELL
$53.63 - $62.52 $9.65 Million - $11.2 Million
-179,866 Reduced 14.27%
1,080,637 $67.4 Million
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $10.3 Million - $12.1 Million
-174,033 Reduced 12.13%
1,260,503 $74.6 Million
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $515,710 - $561,608
8,330 Added 0.58%
1,434,536 $95.9 Million
Q1 2021

May 13, 2021

BUY
$59.34 - $66.74 $1.83 Million - $2.05 Million
30,778 Added 2.21%
1,426,206 $90 Million
Q4 2020

Feb 09, 2021

BUY
$57.74 - $65.43 $3.48 Million - $3.94 Million
60,211 Added 4.51%
1,395,428 $86.6 Million
Q3 2020

Nov 06, 2020

BUY
$57.43 - $63.64 $5.38 Million - $5.97 Million
93,741 Added 7.55%
1,335,217 $80.5 Million
Q2 2020

Aug 12, 2020

BUY
$54.82 - $64.09 $14.8 Million - $17.3 Million
269,624 Added 27.74%
1,241,476 $73 Million
Q1 2020

May 11, 2020

BUY
$46.4 - $67.43 $4.64 Million - $6.74 Million
99,922 Added 11.46%
971,852 $54.2 Million
Q4 2019

Feb 13, 2020

BUY
$49.21 - $64.19 $11.4 Million - $14.8 Million
231,285 Added 36.1%
871,930 $56 Million
Q3 2019

Nov 12, 2019

SELL
$42.77 - $50.71 $297,978 - $353,296
-6,967 Reduced 1.08%
640,645 $32.5 Million
Q2 2019

Aug 13, 2019

BUY
$44.62 - $49.34 $687,058 - $759,737
15,398 Added 2.44%
647,612 $29.4 Million
Q1 2019

May 14, 2019

BUY
$45.12 - $53.8 $1.43 Million - $1.71 Million
31,772 Added 5.29%
632,214 $30.2 Million
Q4 2018

Feb 14, 2019

SELL
$48.76 - $63.23 $3.3 Million - $4.28 Million
-67,639 Reduced 10.12%
600,442 $31.2 Million
Q3 2018

Nov 13, 2018

SELL
$55.19 - $62.25 $347,697 - $392,175
-6,300 Reduced 0.93%
668,081 $41.5 Million
Q2 2018

Aug 13, 2018

SELL
$50.53 - $62.98 $2.17 Million - $2.71 Million
-43,011 Reduced 6.0%
674,381 $37.3 Million
Q1 2018

May 15, 2018

SELL
$59.92 - $68.98 $2.76 Million - $3.18 Million
-46,085 Reduced 6.04%
717,392 $45.4 Million
Q4 2017

Feb 14, 2018

BUY
$59.94 - $65.35 $1.37 Million - $1.49 Million
22,832 Added 3.08%
763,477 $46.8 Million
Q3 2017

Nov 13, 2017

BUY
$55.23 - $63.74 $40.9 Million - $47.2 Million
740,645
740,645 $47.2 Million

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $125B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Blair William & CO Portfolio

Follow Blair William & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

News

Stay updated on Blair William & CO with notifications on news.